Melatonin synergizes BRAF‐targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling. The gene discussed is AKT1; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.